KORU (KRMD) Q2 2026 Earnings Call Transcript
KORU (KRMD) held its Q2 2026 earnings call, saying revenue was $12 million, up 18% for the quarter and 20% for the first half. The company reported gross margin up nearly 200 bps versus its 2026 range and positive net income for the first time since 2019. It discussed growth in domestic and international markets and a connected monitoring technology acquisition.
How this was made
The 30-second read
Why it matters
Traders can update expectations for revenue durability (recurring patient base), margin trajectory (gross margin up, first positive net income since 2019), and strategic optionality (connected monitoring tech acquisition) while monitoring near-term international pacing risk.
Market read
The call provides concrete Q2 financial performance and a strategic technology acquisition, with guidance-like commentary that international growth may moderate in the near term.
What to watch
The excerpt references a technology asset acquisition and RYSTIGGO contribution but does not quantify integration costs, timeline, or the magnitude of connected-monitoring adoption, which could affect execution risk.
Background
KORU is positioning its mechanical SCIG platform for alternate-site and home administration, while selectively adding smart connectivity and expanding into non-IG chronic therapies.
Ticker impact
KORU reports Q2 2026 revenue of $12M (+18% QoQ), improved gross margin, and first positive net income since 2019, plus a connected monitoring tech acquisition.
Moderately positive bias for the next few sessions as traders digest profitability inflection and the strategic technology acquisition, with attention on international ramp commentary.
The text includes concrete financial datapoints (revenue growth, gross margin improvement, first positive net income) and a specific strategic acquisition, but it is still a transcript and lacks full guidance detail in the provided excerpt.
Market effects
Highlights continued shift of subcutaneous immunoglobulin delivery toward alternate sites and home, reinforcing demand for connected drug-delivery platforms.
International expansion is strong but expected to moderate near term due to regional launch and reimbursement/distribution ramp dynamics.
Supports the broader SID/SCIG market narrative that secondary immunodeficiency is expanding beyond SCID, with multiple pivotal trials expected in 12 to 18 months.
Counterpoint
The profitability improvement may be partly timing-related, while international growth moderation and lumpy ramp in newer prefilled syringe markets could cap near-term upside.
Key entities
- companyKORU
SCIG drug-delivery platform provider reporting Q2 2026 results and announcing a connected monitoring technology asset acquisition.
- companyApellis
Referenced as an example of a pharma acquisition that may affect near-term clinical trial timing for partners.